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Summary This paper describes the effectiveness of ﬁrst-line regimens for stage 2 human
African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense infection in nine Médecins
Sans Frontières HAT treatment programmes in Angola, Republic of Congo, Sudan and Uganda.
Regimens included eﬂornithine and standard- and short-course melarsoprol. Outcomes for
10 461 naïve stage 2 patients ﬁtting a standardised case deﬁnition and allocated to one of
the above regimens were analysed by intention-to-treat analysis. Effectiveness was quantiﬁed
by the case fatality rate (CFR) during treatment, the proportion probably and deﬁnitely cured
and the Kaplan—Meier probability of relapse-free survival at 12 months and 24 months post
admission. The CFR was similar for the standard- and short-course melarsoprol regimens (4.9%
and 4.2%, respectively). The CFR for eﬂornithine was 1.2%. Kaplan—Meier survival probabilities
varied from 71.4—91.8% at 1 year and 56.5—87.9% at 2 years for standard-course melarsoprol,
to 73.0—91.1% at 1 year for short-course melarsoprol, and 79.9—97.4% at 1 year and 68.6—93.7%
at 2 years for eﬂornithine. With the exception of one programme, survival at 12 months was
>90% for eﬂornithine, whilst for melarsoprol it was <90% except in two sites. Eﬂornithine is
recommended where feasible, especially in areas with low melarsoprol effectiveness.
© 2008 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights
reserved.
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1. Introduction
Human African trypanosomiasis (HAT), or sleeping sickness,
is caused by Trypanosoma brucei gambiense and is trans-
mitted by the tsetse ﬂy (Glossina spp.). Over 200 foci of
transmission occur in some of the most resource-poor and
conﬂict-ridden areas of Africa; the most affected regions
are the Democratic Republic of the Congo, Sudan, northwest
Uganda and Angola. The WHO reports that approximately
17 000 gambiense cases were identiﬁed in 2004, but the true
number may be considerably higher.1
Available drugs for stage 2 HAT include melarsoprol, a
lipophilic organoarsenical, and eﬂornithine, an inhibitor of
ornithine decarboxylase.2 Melarsoprol is highly toxic, caus-
ing fatal reactive encephalopathy in up to 10% of cases.3
Treatment failure with melarsoprol is common although
localised, occurring in Angola, the Democratic Republic of
the Congo, Sudan and Uganda.4—10 The standard melarso-
prol regimen consists of three weekly series of injections.
A newer short-course alternative (10 days) shows equiva-
lent effectiveness and is increasingly used.11 Eﬂornithine
requires numerous i.v. infusions, which hampers its fea-
sibility in resource-poor settings. Generally, effectiveness
appears to be high and the safety proﬁle appears to be more
favourable than that of melarsoprol.12,13
Médecins Sans Frontières (MSF) is a humanitarian med-
ical relief agency that works in areas of conﬂict, neglect,
disease outbreaks and natural disasters. Since 1986, MSF has
responded to several HAT outbreaks. All these programmes
collected individual patient data to monitor treatment and
to facilitate follow-up. Here we present baseline data, end-
of-treatment outcomes and various effectiveness measures
for the three main ﬁrst-line stage 2 treatment regimens
(eﬂornithine and standard- and short-course melarsoprol)
from nine MSF HAT programmes in four countries. We also
investigate chronological trends in regimen effectiveness.
Effectiveness data on a proportion of patients treated
in the Congo and Sudan programmes are already pub-
lished elsewhere, although with heterogeneous durations
of follow-up, inclusion and endpoint criteria, and analysis
methods.12—14 Speciﬁcally, in Ibba, Sudan, Priotto et al. per-
formed a prospective cohort study of eﬂornithine-treated
patients that included reinforced follow-up measures not
applied to all patients in the programme.13 Our aim here is to
present a joint analysis of all MSF-treated patients in avail-
able data sets, using a common approach and comparing
different effectiveness measurement methods.
2. Methods
2.1. Data sources
Individual patient data from the MSF HAT treatment
programmes in the following locations were pooled: Cax-
ito, Angola (2002—2006); Gamboma (2001—2003), Mossaka
(2003—2005) and Nkayi (2002—2005), the Republic of
the Congo; Adjumani (1991—1999), Arua (1995—2002) and
Yumbe (2000—2002), Uganda; and Kiri (2000—2006) and Ibba
(2000—2006), southern Sudan.
Data had originally been single-entered by ﬁeld staff into
Excel, YoTrypsI, YoTrypsII (both Microsoft Access-based) or
c
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piTryps databases. They were made anonymous, appended
nd cleaned on Stata 9.0 (StataCorp., College Station, TX,
SA). Multiple records based on common variables (admis-
ion and discharge dates, sex, age, laboratory results,
reatment regimen) were eliminated.
.2. Diagnosis, treatment and follow-up
atients were either actively or passively screened for HAT
nfection using the card agglutination test for trypanosomia-
is (CATT). Programmes used different diagnostic algorithms
nd stage 2 deﬁnitions. The standard melarsoprol regimen
as administered using one of the following schedules: (i)
hree series each comprising 4 days of increasing injections
f 1.2mg/kg on Day 1, 2.4mg/kg on Day 2, 3.6mg/kg on
ay 3 and 3.6mg/kg on Day 4, with a 7—10 day rest period
etween each series (Angola, Republic of Congo); (ii) three
eries of 3 days of injections at 3.6mg/kg/day each, with
eries spaced by a 7—10 day rest period (Sudan); and (iii)
nother incremental scheme involving three 3-day injection
eries spaced by 7—10 day periods (series one, 1.8mg/kg on
ay 1, 2.16mg/kg on Day 2 and 2.52mg/kg on Day 3; series
wo, 2.52mg/kg, 2.88mg/kg and 3.42mg/kg; series three,
.6mg/kg, 3.6mg/kg and 3.6mg/kg) (Uganda). The newer,
hort-course melarsoprol schedule consisted of 2.16mg/kg
njections every day for 10 days. Prednisolone was co-
dministered with any melarsoprol regimen to reduce the
isk of reactive encephalopathy. Eﬂornithine was adminis-
ered as four evenly spaced 100mg/kg/day i.v. infusions
150mg/kg in children aged <12 years) for 14 consecutive
ays.
If discharged alive, patients were invited back for follow-
p visits at 3, 6, 12, 18 and 24 months or at 6, 12 and 24
onths following discharge, depending on the programme.
.3. Eligibility criteria
atients were included in the analysis if they fulﬁlled the
ollowing stage 2 case deﬁnition: (i) parasites in the cere-
rospinal ﬂuid (CSF); and/or (ii) CSF white blood cell (WBC)
ount >5/l in the presence of a positive parasitological test
Quantitative Buffy Coat, Capillary Tube Centrifugation or
oo test, microscopy of lymph tissue, mini-Anion Exchange
olumn Test) in blood or lymph gland aspirate; and/or (iii)
SF WBC count >20/l in the presence of a positive CATT
est at dilution ≥1:4. Furthermore, patients were included
nly if they had no record of prior HAT treatment and were
llocated to one of the above regimens.
.4. Effectiveness analysis
n intention-to-treat approach to the analysis was used
ince the aim was to establish effectiveness in ﬁeld condi-
ions. The following were considered as treatment failures:
i) death due to any cause between admission and dis-
harge; (ii) incomplete treatment course due to any cause;
iii) death due to any cause during follow-up; (iv) micro-
copic observation of trypanosomes in any body tissues at
ny follow-up visit; (v) CSF WBC count at any follow-up visit
50/l and greater than at admission; or (vi) programme’s
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Table 1 Proﬁle of 6324 patients treated with melarsoprol (standard regimen) and eligible for analysis [n (%)]
Caxito, Angola
(n = 223)
Gamboma,
Congo (n = 106)
Mossaka, Congo
(n = 16)
Nkayi, Congo
(n = 174)
Ibba, Sudan
(n = 883)
Adjumani, Uganda
(n = 3305)
Arua, Uganda
(n = 1577)
Yumbe, Uganda
(n = 40)
Baseline characteristicsa
Age (years)
≤12 28 (12.6) 17 (16.0) 2 (12.5) 17 (9.8) 146 (16.5) 547 (16.6) 273 (17.3) 6 (15.0)
13—24 54 (24.2) 23 (21.7) 5 (31.3) 44 (25.3) 269 (30.5) 1196 (36.2) 498 (31.6) 11 (27.5)
25—44 96 (43.0) 38 (35.8) 8 (50.0) 73 (42.0) 311 (35.2) 1202 (36.4) 598 (37.9) 16 (40.0)
≥45 45 (20.2) 28 (26.4) 1 (6.3) 40 (23.0) 157 (17.8) 360 (10.9) 208 (13.2) 7 (17.5)
Female 95 (42.6) 54 (50.9) 6 (37.5) 76 (43.7) 447 (50.6) 1725 (52.2) 784 (49.7) 20 (50.0)
Screened actively 60 (26.9) 73 (68.9) 0 113 (64.9) 272 (30.8) 1108 (33.5) 284 (18.0) 7 (17.5)
GP-positive 147 (65.9) 57 (53.8) 7 (43.8) 116 (66.7) 636 (72.0) 2358 (71.3) 746 (47.3) 26 (65.0)
CTC-positive 63 (28.3) 37 (34.9) 5 (31.3) 41 (23.6) 157 (17.8) 600 (18.2) 458 (29.0) 13 (32.5)
mAECT-positive ND ND ND ND ND ND ND ND
QBC-positive ND ND ND ND 30 (3.4) 95 (2.9) 571 (36.2) ND
Parasites in CSF 153 (68.6) 35 (33.0) 14 (87.5) 53 (30.5) 310 (35.1) 1604 (48.5) 1121 (71.1) 23 (57.5)
WBC in CSF (cells/l)
0 0 0 0 0 0 10 (0.3) 4 (0.3) 0
1—5 0 0 0 0 0 71 (2.1) 13 (0.8) 0
6—10 6 (2.7) 25 (23.6) 0 38 (21.8) 194 (22.0) 509 (15.4) 112 (7.1) 11 (27.5)
11—20 9 (4.0) 11 (10.4) 3 (18.8) 35 (20.1) 161 (18.2) 482 (14.6) 145 (9.2) 3 (7.5)
21—50 38 (17.0) 12 (11.3) 1 (6.3) 29 (16.7) 183 (20.7) 661 (20.0) 257 (16.3) 2 (5.0)
≥51 169 (75.8) 58 (54.7) 12 (75.0) 72 (41.4) 345 (39.1) 1566 (47.4) 1043 (66.1) 24 (60.0)
Follow-up attrition
Completed treatment
and discharged alive
214 (96.0) 98 (92.5) 16 (100) 163 (93.7) 843 (95.5) 3097 (93.7) 1506 (95.5) 40 (100)
Seen at least once after
dischargeb
181 (84.6) 81 (82.7) 16 (100) 162 (99.4) 552 (65.5) 1829 (59.1) 1325 (88.0) 36 (90.0)
Seen at 12 monthsb 86 (40.2) 25 (25.5) 7 (43.8) 118 (72.4) 42 (5.0) 611 (19.7) 725 (48.1) 12 (30.0)
Seen at 24 monthsb 43 (20.1) 5 (5.1) 0 67 (41.1) 87 (10.3) 293 (9.5) 512 (34.0) 4 (10.0)
Median no. of days
followed up post discharge
(IQR)b
424 (178—695) 220 (93—408) 532 (302—555) 571 (366—732) 204 (0—692) 185 (0—404) 391 (186—730) 259 (158—417)
GP: gland puncture; CTC: capillary tube centrifugation test; mAECT: mini-anion exchange centrifugation technique; QBC: quantitative buffy coat test; CSF: cerebrospinal ﬂuid; WBC:
white blood cells; IQR: interquartile range; ND: not done.
a Missing values as follows: sex (4 Adjumani, 1 Arua); screening mode (14 Adjumani); parasites in CSF (1 Caxito, 3 Ibba, 19 Adjumani); and WBC in CSF (1 Caxito, 6 Adjumani, 3 Arua).
b Of those who completed treatment and were discharged alive; includes patients discharged <24 months before the programme or data set’s end.
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Table 2 Proﬁle of 973 patients treated with melarsoprol (short-course regimen) and eligible for analysis [n (%)]a
Gamboma, Congo (n = 44) Kiri, Sudan (n = 929)
Baseline characteristics
Age (years)
≤12 1 (2.3) 193 (20.8)
13—24 13 (29.5) 292 (31.4)
25—44 21 (47.7) 313 (33.7)
≥45 9 (20.5) 131 (14.1)
Female 22 (50.0) 475 (51.1)
Screened actively 30 (68.2) 164 (17.7)
GP-positive 30 (68.2) 472 (50.8)
CTC-positive 8 (18.2) 59 (6.4)
mAECT-positive ND ND
QBC-positive ND 315 (33.9)
Parasites in CSF 8 (18.2) 390 (42.0)
WBC in CSF (cells/l)
0 0 0
1—5 0 2 (0.2)
6—10 12 (27.3) 123 (13.2)
11—20 5 (11.4) 162 (17.4)
21—50 11 (25.0) 193 (20.8)
≥51 16 (36.4) 449 (48.3)
Follow-up attrition
Completed treatment and discharged alive 38 (86.4) 885 (95.3)
Seen at least once after dischargeb 34 (89.5) 708 (80.0)
Seen at 12 monthsb 1 (2.6) 296 (33.4)
Seen at 24 monthsb 0 158 (17.9)
Median no. of days followed up post discharge (IQR)b 210 (44—333) 358 (172—724)
GP: gland puncture; CTC: capillary tube centrifugation test; mAECT: mini-anion exchange centrifugation technique; QBC: quantitative
buffy coat test; CSF: cerebrospinal ﬂuid; WBC: white blood cells; IQR: interquartile range; ND: not done.
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b Of those who completed treatment and were discharged alive; in
set’s end.
decision to institute second-line treatment owing to clinical
status and/or rising CSF cell counts on consecutive follow-up
visits. Individual patient ﬁles could not be checked to ver-
ify that these instances of clinician discretion were indeed
due to a relapsing infection, but it was assumed that they
were. This was to accommodate cases where a HAT relapse
is clinically evident despite no parasitological conﬁrmation
or WBC counts below the failure thresholds. Patients were
considered cured at any follow-up visit if they were seen
and did not meet any of the failure criteria.
Effectiveness was expressed in three ways. First, crude
effectiveness proportions were calculated assuming that
patients lost to follow-up were cured. Second, the same
proportions were calculated excluding losses to follow-up
both from the numerator and the denominator. For both
of the above expressions, effectiveness was calculated at
12 months post discharge by excluding patients discharged
<12 months before either the end of the programme or,
for programmes that were ongoing at the time of analysis
(Caxito, Angola; Kiri, Sudan; Ibba, Sudan), the last database
update (since their follow-up might have been incomplete).
Any follow-up visit occurring between 10—14 months after
discharge was considered as a valid 12-month control. Effec-
tiveness was also calculated at 24 months by excluding
g
t
t
ﬁ
wle on the basis of small sample size.
es patients discharged <24 months before the programme or data
atients discharged <24 months before the end of the pro-
ramme or the last database update, and considering any
isit between 22—26 months as a valid 24-month control.
Third, Kaplan—Meier probabilities of failure-free survival
ere computed by considering the date of admission as the
tart of the at-risk period, and censoring patients when they
ailed or at the last follow-up visit they attended. Survival
robabilities at 12 months and 24 months were computed
y censoring all observations at 14 months and 26 months,
espectively. When the number of patients under follow-up
t the last time point was low, the survival probability at the
ast time point when precision of the estimate lay within
5% was calculated as a more reliable Kaplan—Meier esti-
ate. Note that some follow-ups and failures occurred >26
onths after discharge. These are often considered novel
nfections.
We mostly abstained from statistical testing since
atients were not randomly allocated to regimens and since
he aim was merely to describe effectiveness. For pro-
rammes that treated considerable numbers of patients with
he same regimen over a period of at least six semesters,
he 12-month Kaplan—Meier survival probability was strati-
ed by semester of admission, and a log-rank test for trend
as performed.
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Table 3 Proﬁle of 3164 patients treated with eﬂornithine and eligible for analysis [n (%)]
Caxito, Angola
(n = 279)
Gamboma,
Congo (n = 15)
Mossaka,
Congo
(n = 137)
Nkayi, Congo
(n = 116)
Ibba, Sudan
(n = 2090)
Kiri, Sudan
(n = 482)
Arua, Uganda
(n = 45)
Baseline characteristicsa
Age (years)
≤12 21 (7.5) 10 (66.7) 19 (13.9) 31 (26.7) 327 (15.6) 104 (21.6) 4 (8.9)
13—24 60 (21.5) 2 (13.3) 30 (21.9) 25 (21.6) 823 (39.4) 144 (29.9) 15 (33.3)
25—44 123 (44.1) 2 (13.3) 59 (43.1) 39 (33.6) 714 (34.2) 171 (35.5) 20 (44.5)
≥45 75 (26.9) 1 (6.7) 29 (21.2) 21 (18.1) 226 (10.8) 63 (13.1) 6 (13.3)
Female 99 (35.5) 7 (46.7) 66 (48.2) 60 (51.7) 907 (43.4) 178 (36.9) 19 (42.2)
Screened actively 89 (31.9) 4 (26.7) 81 (59.1) 66 (56.9) 370 (17.7) 181 (37.6) 1 (2.2)
GP-positive 184 (65.9) 6 (40.0) 80 (58.4) 76 (65.5) 1163 (55.6) 229 (47.5) 18 (40.0)
CTC-positive 68 (24.4) 7 (46.7) 31 (22.6) 28 (24.1) 767 (36.7) 134 (27.8) 12 (26.7)
mAECT-positive 4 (1.4) ND ND ND ND ND 9 (20.0)
QBC-positive ND ND ND 8 (6.9) 49 (2.3) 56 (11.6) ND
Parasites in CSF 206 (73.8) 11 (73.3) 93 (67.9) 54 (46.6) 729 (34.9) 257 (53.3) 40 (88.9)
WBC in CSF (cells/l)
0 0 0 0 0 0 0 0
1—5 0 0 0 1 (0.9) 0 0 0
6—10 13 (4.7) 1 (6.7) 1 (0.7) 1 (0.9) 495 (23.7) 50 (10.4) 0
11—20 32 (11.5) 2 (13.3) 32 (23.4) 32 (27.6) 347 (16.6) 59 (12.2) 3 (6.7)
21—50 37 (13.3) 0 19 (13.9) 21 (18.1) 311 (14.9) 57 (11.8) 3 (6.7)
≥51 197 (70.6) 12 (80.0) 85 (62.0) 61 (52.6) 937 (44.8) 316 (65.6) 39 (86.7)
Follow-up attrition
Completed
treatment and
discharged alive
275 (98.6) 15 (100) 135 (98.5) 113 (97.4) 2057 (98.4) 478 (99.2) 44 (97.8)
Seen at least once
after dischargeb
128 (46.6) 12 (80.0) 105 (77.8) 75 (66.4) 1617 (78.6) 313 (65.5) 15 (34.1)
Seen at 12 monthsb 36 (13.1) 2 (13.3) 34 (25.2) 32 (28.3) 583 (28.3) 114 (23.8) 5 (11.4)
Seen at 24 monthsb 0 2 (13.3) 0 2 (1.8) 276 (13.4) 23 (4.8) 9 (20.5)
Median no. of days
followed up post
discharge (IQR)b
0 (0—216) 189 (91—368) 194 (98—363) 177 (0—360) 359
(184—683)
191 (0—372) 0 (0—213)
GP: gland puncture; CTC: capillary tube centrifugation test; mAECT: mini-anion exchange centrifugation technique; QBC: quantitative buffy coat test; CSF: cerebrospinal ﬂuid; WBC:
white blood cells; IQR: interquartile range; ND: not done.
a Missing values as follows: sex (1 Ibba); screening mode (3 Ibba); and parasites in CSF (1 Mossaka, 1 Ibba).
b Of those who completed treatment and were discharged alive; includes patients discharged <24 months before the programme or data set’s end.
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Table 4 Endpoints and effectiveness measures for patients treated with melarsoprol (standard regimen)
Caxito, Angola Gamboma, Congo Mossaka, Congo Nkayi, Congo Ibba, Sudan Adjumani, Uganda Arua, Uganda Yumbe, Uganda
Case fatality rate during treatment
Total dead/total admitted 8/223 (3.6%) 5/106 (4.7%) 0/16 10/174 (5.7%) 40/883 (4.5%) 179/3305 (5.4%) 66/1577 (4.2%) 0/40
Effectiveness at 12 months post discharge
Discharged ≥12 months before
programme/data set end
219 106 16 174 883 3181 1546 40
Lost to follow-up 115 72 6 25 704 2346 544 23
Cured 80 22 7 112 27 602 620 12
Failed 24 12 3 37 152 233 382 5
Total cured/total treated,
assuming lost to follow-up are
cured
195/219 (89.0%) 94/106 (88.7%) 13/16 (81.3%) 137/174 (78.7%) 731/883 (82.8%) 2948/3181 (92.7%) 1164/1546 (75.3%) 35/40 (87.5%)
Total cured/total treated,
excluding lost to follow-up
80/104 (76.9%) 22/34 (64.7%) 7/10 (70.0%) 112/149 (75.2%) 27/179 (15.1%) 602/835 (72.1%) 620/1002 (61.9%) 12/17 (70.6%)
Survival probability in %
(Kaplan—Meier)
86.2 73.3 80.8 77.8 75.6 91.8 71.4 85.3
Effectiveness at 24 months post discharge
Discharged ≥24 months before
programme/data set end
178 82 4 98 883 3044 1422 14
Lost to follow-up 106 68 1 19 612 2522 492 10
Cured 41 3 0 48 79 285 471 4
Failed 31 11 3 31 192 237 459 0
Total cured/total treated,
assuming lost to follow-up are
cured
147/178 (82.6%) 71/82 (86.6%) 1/4 (25.0%) 67/98 (68.4%) 691/883 (78.3%) 2807/3044 (92.2%) 963/1422 (67.7%) 14/14 (100%)
Total cured/total treated,
excluding lost to follow-up
41/72 (56.9%) 3/14 (21.4%) 0/3 48/79 (60.8%) 79/271 (29.2%) 285/522 (54.6%) 471/930 (50.6%) 4/4 (100%)
Survival probability in %
(Kaplan—Meier)
75.1 74.5 56.5 b 66.0 65.3 87.9 60.3 85.3
Reasons for failure (% of all failures)a
Death during treatment 8 (23.5) 5 (35.7) 0 10 (20.4) 40 (19.3) 179 (70.5) 66 (13.4) 0
Treatment incomplete 1 (2.9) 3 (21.4) 0 1 (2.0) 0 29 (11.4) 5 (1.0) 0
Death during follow-up 0 0 0 2 (4.1) 6 (2.9) 0 38 (7.7) 0
Parasites during follow-up 10 (29.4) 1 (7.1) 5 (71.4) 7 (14.3) 128 (61.8) 22 (8.7) 282 (57.3) 5 (100)
WBC increase during follow-up 11 (32.4) 5 (35.7) 2 (28.6) 25 (51.0) 18 (8.7) 20 (7.9) 74 (15.0) 0
Clinician’s decision during
follow-up
4 (11.8) 0 0 4 (8.2) 15 (7.2) 4 (1.6) 27 (5.5) 0
Total failures 34 14 7 49 207 254 492 5
WBC: white blood cells.
a Includes failures that occurred after 24 months of discharge.
b Estimate unreliable due to small denominator.
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Table 5 Endpoints and effectiveness measures for patients treated with melarsoprol (short-course regimen)a
Gamboma, Congo Kiri, Sudan
Case fatality rate during treatment
Total dead/total admitted 3/44 (6.8%) 38/929 (4.1%)
Effectiveness at 12 months post discharge
Discharged ≥12 months before programme/data set end 44 920
Lost to follow-up 26 554
Cured 7 293
Failed 11 73
Total cured/total treated, assuming lost to follow-up are cured 33/44 (75.0%) 847/920 (92.1%)
Total cured/total treated, excluding lost to follow-up 7/18 (38.9%) 293/366 (80.1%)
Survival probability in % (Kaplan—Meier) 64.8 [73.0 at 11 months]c 91.1
Effectiveness at 24 months post discharge
Discharged ≥24 months before programme/data set end 44 916
Lost to follow-up 32 682
Cured 0 158
Failed 12 76
Total cured/total treated, assuming lost to follow-up are cured 32/44 (72.7%) 840/916 (91.7%)
Total cured/total treated, excluding lost to follow-up 0/12 158/234 (67.5%)
Survival probability in % (Kaplan—Meier) 54.0 [73.0 at 11 months]c 90.3
Reasons for failure (% of all failures)b
Death during treatment 3 (25.0) 38 (49.4)
Treatment incomplete 3 (25.0) 6 (7.8)
Death during follow-up 0 11 (14.3)
Parasites during follow-up 0 16 (20.8)
WBC increase during follow-up 5 (41.7) 1 (1.3)
Clinician’s decision during follow-up 1 (8.3) 5 (6.5)
Total failures 12 77
WBC: white blood cells.
a Four patients treated in Mossaka, Congo, are not included in this table on the basis of small sample size.
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c Estimate unreliable due to small numbers [refer to estimate in
. Results
.1. Patient proﬁle
fter pooling available data sets, 11 668 patients meet-
ng the criteria of naïve stage 2 HAT were identiﬁed. Of
hese, 1109 received regimens other than standard- or short-
ourse melarsoprol or 14-day eﬂornithine, including patients
reated with pentamidine in Angola and the Republic of the
ongo where the WBC threshold for stage 2 classiﬁcation was
igher than >5/l, and participants in combination therapy
rials. Another 94 could not be analysed owing to missing
ariables. Thus, 10 465 patients were eligible for analysis,
f whom 6324 were allocated to standard-course melarso-
rol, 977 to short-course melarsoprol (of whom a further 4
rom Mossaka were omitted from the results owing to small
ample size) and 3164 to eﬂornithine.
Baseline characteristics for all patients are shown by
reatment given and treatment site in Tables 1—3. Only a
inority of patients treated were children under the age
f 12 years. In the Republic of the Congo, the majority of
atients were detected through active screening; in Uganda
nd Sudan, passive screening was predominant. Gland punc-
ure was an important means of conﬁrming diagnosis, used
s
r
w
a
aets].
n 61% of cases (n = 6351) and demonstrating persisting
arasitaemia in the haemolymphatic system during stage 2
AT. The presence of parasites in CSF was common (49%;
= 5101), as was a high WBC count (>50 cells/l) in the CSF
52%; n = 5401), and the two stage 2 markers were strongly
orrelated [80.3% (4098/5101 patients) with parasites in
SF also had a WBC count >50/l compared with 24.3%
1295/5334 patients) in those without; P < 0.001]. There was
ariation between sites and treatments for all baseline vari-
bles. For important indicators of severity such as CSF WBC
ount ≥51/l, there were no striking differences between
reatment groups. For example, for standard-course melar-
oprol, the value ranged from 39.1% to 75.8% across the
ites (overall mean 52%); for short-course melarsoprol it was
6.4% and 48.3% for the two sites (overall mean 49%); and
or eﬂornithine it ranged between 44.8% and 86.7% (overall
ean 52%). Only a total of 56 (0.5%) of 10 461 patients did
ot complete a full course of treatment. This included 39
0.6%) in the standard-course melarsoprol, 9 (0.9%) in the
hort-course melarsoprol and 8 (0.3%) in the eﬂornithine
egimens. Follow-up both at 12 months and 24 months
as low and only exceeded 50% in the one site of Nkayi,
lthough >50% of patients were followed-up at least once
fter discharge everywhere except for Caxito (eﬂornithine)
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and Arua (eﬂornithine). Follow-up attendance declined over
time. Follow-up for eﬂornithine-treated patients appears
artiﬁcially low due to the fact that many were still under
follow-up when the MSF programme was handed over to
other agencies, or when the data sets for this analysis were
captured.
3.2. Case fatality rates during treatment
For melarsoprol, some variation in case fatality rate (CFR)
was observed due to the small sample sizes treated in
some centres (Gamboma, Yumbe). However, where larger
sample sizes existed (>150), the CFR was 3.6—5.7%. Rates
for the standard- and short-course regimens were similar
at 4.9% (n = 308/6324) and 4.2% (n = 41/973), respectively.
Eﬂornithine CFRs varied between centres at 0—2.6%, and
the overall CFR was 1.2% (n = 39/3164).
3.3. Effectiveness
Crude cure (effectiveness) rates varied strongly for each
treatment regimen depending on whether patients lost to
follow-up were assumed cured or were excluded from the
analysis (Tables 4—6). For example, comparing the former
assumption and the latter method, the cure rate at 12
months for the standard melarsoprol regimen was between
75.3—92.7% compared with 15.1—76.9%. For the short-
course melarsoprol regimen the rates were 75.0—92.1%
and 38.9—80.0%, respectively; and for eﬂornithine (12-
month cure) they were 90.6—97.7% and 66.7—92.3%,
respectively.
Kaplan—Meier survival probabilities for melarsoprol var-
ied between 71.4—91.8% at 1 year and 56.5—87.9% at 2
years for the standard-course regimen to 73.0—91.1% at 1
year for the short-course regimen. For eﬂornithine, this var-
ied from 79.9—97.4% at 1 year and 68.6—93.7% at 2 years.
Estimates became unreliable at 24 months owing to heavy
loss to follow-up. However, with the exception of Mossaka,
survival at 12 months was >90% for eﬂornithine, whilst for
melarsoprol it was <90% except in Kiri and Adjumani.
Of 854 relapses post discharge in the entire analysis
group, 567 (66.4%) were diagnosed based on observation of
parasites, 209 (24.5%) based on raised WBC count and 78
(9.1%) via clinician’s discretion, with no differences among
regimens (data not shown).
In a Cox proportional hazards model of the probabil-
ity of failure up to the 12-month visit, after adjusting for
project and treatment regimen, out of all baseline variables
(Tables 1—3) age ≤12 years [hazard ratio (HR) 0.76, 95% CI
0.60—0.96], female gender (HR 0.77, 95% CI 0.65—0.90),
passive case detection (HR 1.30, 95% CI 1.05—1.62), try-
panosomes in the CSF (HR 1.30, 95% CI 1.06—1.59) and CSF
WBC count >50/l (HR 2.21, 95% CI 1.77—2.75) were associ-
ated with failure. From the above, only age ≤12 years (HR
0.86, 95% CI 0.80—0.94) and passive case detection (HR 1.15,
95% CI 1.08—1.23) were also associated with loss to follow-
up before the 12-month visit in a similar survival model.
There was no obvious correlation between the Kaplan—Meier
probabilities of follow-up and failure-free survival at 12
months (see Figure 1) or 24 months (data not shown) across
projects for the same regimen, although eﬂornithine cohorts
c
s
i
b
wigure 1 Correlation between the probabilities of failure-free
urvival and follow-up at the 12-month visit.
ad worse follow-up and better observed effectiveness than
he melarsoprol groups (Figure 1).
There was no evidence of a rising or declining trend in
2-month effectiveness in the four programmes that used
ny of the three regimens as ﬁrst-line choice for at least six
onsecutive semesters. For example, with standard-course
elarsoprol in Adjumani, survival was 93.2%, 89.6%, 92.0%,
2.2%, 94.2%, 90.7%, 90.6%, 91.4%, 91.8% and 98.3% for
emesters 1 to 10, respectively (log-rank test for trend,
= 0.406). In Arua (also standard-course melarsoprol), sur-
ival was 80.2%, 69.1%, 63.4%, 71.9%, 77.6%, 61.1%, 66.7%,
7.2%, 73.1% and 67.1% for semesters 1 to 10, respectively
log-rank test for trend, P = 0.839 excluding semester 1).
ith short-course melarsoprol in Kiri, survival was 90.6%,
7.8%, 89.6%, 95.6%, 94.0% and 95.0% for semesters 1 to 6,
espectively (log-rank test for trend, P = 0.079). With eﬂor-
ithine in Ibba, survival was 94.7%, 91.8%, 91.9%, 94.5%,
1.1%, 93.6% and 90.0% for semesters 1 to 7, respectively
log-rank test for trend, P = 0.457).
. Discussion
he data set presented is unique in being large and col-
ected from a range of different locations. Our analysis
onsists of a large multicentre descriptive study presenting
he outcome of the two main drugs used in HAT gambi-
nse infections. Our analysis uses an alternative statistical
ethod, Kaplan—Meier survival analysis, to what has typ-
cally been used in HAT treatment effectiveness analysis.
n the past, various analytical approaches have been used
o deal with incomplete follow-up attrition, ranging from
nly analysing patients who were followed-up to considering
hose lost to follow-up as cured. These methods calculate
reatment failure rates as a percentage of treatment fail-
res among the number of patients either treated or seen
t follow-up.
The results show a lower CFR for patients treated with
ﬂornithine compared with melarsoprol. The CFR for short-
ourse melarsoprol in Kiri showed no difference from the
tandard regimen. The short-course melarsoprol patients
n other centres are incomparable due to the low num-
er of patients treated. These ﬁndings are in agreement
ith the current literature on efﬁcacy and toxicity levels
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Table 6 Endpoints and effectiveness measures for patients treated with eﬂornithine
Caxito, Angola Gamboma, Congo Mossaka, Congo Nkayi, Congo Ibba, Sudan Kiri, Sudan Arua, Uganda
Case fatality rate during treatment
Total dead/total admitted 4/279 (1.4%) 0/15 0/137 3/116 (2.6%) 27/2090 (1.3%) 4/482 (0.8%) 1/45 (2.2%)
Effectiveness at 12 months post discharge
Discharged ≥12 months
before programme/data set
end
131 15 53 52 2082 369 12
Lost to follow-up 92 12 17 18 1421 248 6
Cured 36 2 31 30 554 105 5
Failed 3 1 5 4 107 16 1
Total cured/total treated,
assuming lost to follow-up
are cured
128/131 (97.7%) 14/15 (93.3%) 48/53 (90.6%) 48/52 (92.3%) 1975/2082 (94.9%) 353/369 (95.7%) 11/12 (91.7%)
Total cured/total treated,
excluding lost to follow-up
36/39 (92.3%) 2/3 (66.7%) 31/36 (86.1%) 30/34 (88.2%) 554/661 (83.8%) 105/121 (86.8%) 5/6 (83.3%)
Survival probability in %
(Kaplan—Meier)
97.4 91.7 79.9 90.7 92.9 90.7 93.3
Effectiveness at 24 months post discharge
Discharged ≥24 months
before programme/data set
end
1 11 1 7 1448 198 10
Lost to follow-up 1 8 0 5 1064 163 1
Cured 0 2 0 0 255 18 8
Failed 0 1 1 2 129 17 1
Total cured/total treated,
assuming lost to follow-up
are cured
1/1 (100%) 10/11 (90.9%) 0/1 5/7 (71.4%) 1319/1448 (91.1%) 181/198 (91.4%) 9/10 (90.0%)
Total cured/total treated,
excluding lost to follow-up
0/0 2/3 (66.7%) 0/1 0/2 255/384 (66.4%) 18/35 (51.4%) 8/9 (88.9%)
Survival probability in %
(Kaplan—Meier)
93.7 91.7 71.7 [79.7 at 14 months]b 25.9 [90.7 at 18 months]b 85.2 68.6 83.0 [93.3 at 16
months]b
Reasons for failure (% of all failures)a
Death during treatment 4 (57.1) 0 0 3 (33.3) 27 (16.5) 4 (11.4) 1 (25.0)
Treatment incomplete 0 0 2 (20.0) 0 6 (3.7) 0 0
Death during follow-up 0 1 (100) 2 (20.0) 1 (11.1) 19 (11.6) 1 (2.9) 2 (50.0)
Parasites during follow-up 2 (28.6) 0 3 (30.0) 3 (33.3) 59 (36.0) 24 (68.6) 0
WBC increase during
follow-up
0 0 3 (30.0) 2 (22.2) 36 (22.0) 6 (17.1) 1 (25.0)
Clinician’s decision during
follow-up
1 (14.3) 0 0 0 17 (10.4) 0 0
Total failuresa 7 1 10 9 164 35 4
WBC: white blood cells.
a Includes failures that occurred after 24 months of discharge.
b Estimate unreliable due to small numbers [refer to estimate in brackets].
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promoted as ﬁrst-line treatment for late-stage HAT gam-Melarsoprol and eﬂornithine for gambiense sleeping sicknes
of melarsoprol and eﬂornithine.15—20 Areas with documented
melarsoprol refractoriness, such as Arua, Yumbe and Ibba,
do not have particularly elevated CFRs compared with areas
without documented resistance, showing that increased
melarsoprol failure is not associated with fatality during
treatment but with recurrence of disease during the follow-
up period. For the four largest treatment centres, analysis
by semester cohorts treated with the same drug regimen
indicates that failure probability has remained consistent
over the course of a programme.
In the ﬁrst year of follow-up, the standard melarsoprol
regimen has the overall lowest cure rates, but the values
are spread across a wide range. Low cure rates of subfoci
occur in Uganda; Arua and Yumbe have markedly higher fail-
ure rates, in contrast to the low rates in nearby Adjumani.
South Sudan shows similar results between Kiri (low) and
Ibba (high). Both situations appear to indicate that parasite
populations followed the movements of human host popu-
lations, which in this area occur along a North—South axis
across the border, both for war-related migrations and for
ongoing commercial activity. These population ﬂows con-
nect Ibba with Arua and Yumbe on one axis, and Kiri with
Adjumani (and Moyo) on another axis. Low melarsoprol cure
probabilities in Mossaka are difﬁcult to interpret owing to
the low number of individuals studied.
Eﬂornithine has higher effectiveness than melarsoprol
within 1 year of follow-up. In the second year, the cure
probabilities decrease, demonstrating the importance of
continued follow-up to 24 months. It is not possible to state
whether failure probabilities increase more in the second
year for any one drug regimen owing to limited follow-up
rates. For example, Kiri is striking in that cure rates with
eﬂornithine fall dramatically from 90.7% at 12 months to
68.6% at 24 months. Ibba also sees a fall in cure rates with
eﬂornithine from 92.9% to 85.2%. However, the survival rate
for eﬂornithine from Kiri at 2 years was strongly under-
estimated as a result of the very low follow-up rate, as
shown by a recent analysis of an updated database from
Kiri (F. Chappuis, unpublished observation). In general, our
effectiveness estimates at 24 months should be interpreted
with great caution owing to the considerable proportion of
patients not followed up beyond 1 year. And whilst these
decreases in cure rates with eﬂornithine appear dramatic,
it must be borne in mind that cure rates with melarsoprol
are already <90% at 12 months in all sites except Adjumani
and Kiri (Adjumani has low melarsoprol failure rates, but it
also has low rates of follow-up so the failure rates may have
been underestimated).
Eﬂornithine treatment failures could have been associ-
ated with the age of patients, severe disease at admission
or HIV co-infection.21—23 Treatment failures with i.v. eﬂor-
nithine are thought to occur disproportionately among
children, who eliminate eﬂornithine at a faster rate. For
this reason, higher doses have been recommended, particu-
larly among naïve cases.23 However, a recent publication on
eﬂornithine safety and effectiveness now suggests that age
plays a less important role as a risk factor and that higher
doses do not improve effectiveness in children.13 Advanced
disease is a known risk factor for treatment failure.11,13
The Kiri eﬂornithine group had 53.3% and 65.6% of patients
with trypanosomes or a WBC count >50/l in the CSF; the
group averages were 43.9% and 52.1%, respectively. Case
b
p
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eports suggest that HIV-positive patients are less respon-
ive to eﬂornithine, the hypothesis being that eﬂornithine’s
rypanostatic activity requires an active immune system to
lear the parasites. We could not explore this issue as the
IV status of the patients was unknown.11,13,21,22
The Kaplan—Meier method yields failure estimates
etween the two crude methods, but is closer to the ‘tra-
itional’ method of calculating the failure proportion as
umber failed/total treated and hence the assumption that
ases lost to follow-up are cured. The main advantages of
aplan—Meier are that patients with limited follow-up are
ncluded in the analysis group, resulting in less data loss
nd bias, more precision and no assumptions made about
heir ﬁnal outcome. None the less, analysis is still sub-
ect to potential bias if patients not followed up feature
systematically different risk of treatment failure. Cost of
ravel/poor transport, days of missed income, fear of lum-
ar puncture and political instability can account for poor
ollow-up despite programme investment to improve it. Sur-
ival analysis suggested that children and actively screened
ases had lower risk of failure and were overrepresented
mong patients followed up; however, the magnitude of
hese associations was small and both groups were a minority
f all patients, suggesting a relatively mild overestimation
f effectiveness. Melarsoprol-treated cohorts exhibited bet-
er follow-up and lower effectiveness than those receiving
ﬂornithine, which may indicate selection bias and either
verestimation or underestimation of effectiveness (those
ollowed-up could either be the healthiest or, more prob-
bly, the sickest, i.e. relapsing patients). However, there
as no apparent correlation between follow-up and effec-
iveness across projects, for the same regimen, suggesting
ittle systematic bias related to differential follow-up, which
ould increase the reliability of our ﬁndings (see Figure 1).
he reality may be more complex: certain groups of both
ealthy and relapsing patients might adhere to or default
rom the follow-up schedule, creating conﬂicting biases; the
roﬁle of these groups might vary across sites; and the above
ould be further confounded by site-speciﬁc effectiveness
atterns. Investigation of patient reasons for defaulting HAT
reatment monitoring visits would be useful.
There are other important limitations that affect the
nterpretation of the data. The study, being neither
andomised nor controlled, does not allow for robust
omparison between treatments or centres. It is also
omplicated by the fact that populations may have sig-
iﬁcantly varied between areas and over time, allowing
mportant differences in baseline factors to exist. Data
ere often collected in difﬁcult ‘ﬁeld’ circumstances rather
han research settings, thus affecting quality. However, ran-
omised studies are extremely challenging to implement in
hese conditions. There thus exists an important need to
onitor the ‘effectiveness’ of the limited range of stage 2
reatments for HAT.
The results of this descriptive analysis illustrate that
elarsoprol is associated with poorer outcomes than eﬂor-
ithine in most cases, suggesting that eﬂornithine could beiense infections. The remarkable stability of low failure
robabilities in programmes that are near areas with known
efractoriness indicates that refractoriness could be mapped
nd treatment strategies could be adapted accordingly. The
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ifﬁculties experienced in analysing the data owing to losses
o follow-up point to the need for extensive investigation
nto the causes of losing patients to follow-up and a result-
ng strategy for their mitigation. The lack of information on
IV status and HAT infections necessitates a comprehensive
xploration on the matter.24
To treat and control HAT better, less invasive diagnostic
nd staging methods are needed, especially as HAT is most
rominent in resource-poor settings. Less staff-intensive
herapies are also required, as both melarsoprol and eﬂor-
ithine must be administered intravenously. Development of
n efﬁcacious, less toxic, more convenient treatment would
reatly alleviate staff burden and inﬂuence more patients
o seek treatment. A large, multicentre trial studying nifur-
imox and eﬂornithine combination treatment (NECT) is
urrently ongoing.25 NECT is shorter and requires only two
aily eﬂornithine infusions and less total infusions than
he conventional 14-day eﬂornithine treatment. In the near
uture this treatment may offer an alternative to the current
onotherapies.
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